Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Routine blood clot prevention works well for most burn patients. A 12-year study of over 1,000 hospitalized burn patients found that venous thromboembolism (VTE) occurred in just 1.8% of those receiving standard low-molecular-weight heparin (LMWH) prophylaxis. However, risk climbed sharply with burn severity — patients with burns covering more than 20% of their body had a 7.4% VTE rate.
Routine blood clot prevention keeps VTE rates low in burn patients — mostly. A large retrospective study spanning 12 years and over 1,000 hospitalized burn patients found that standard pharmacologic prophylaxis with low-molecular-weight heparin (LMWH) kept the overall rate of clinically significant venous thromboembolism (VTE) to just 1.8%. That's reassuring news for the majority of burn patients.
But the picture changes significantly for those with more severe burns. Patients with burns covering more than 20% of their total body surface area (TBSA) faced a 7.4% VTE rate — and those who did develop a clot spent dramatically longer in the hospital and ICU compared to those who didn't.
By the Numbers:
Why it matters: These findings support the use of universal LMWH prophylaxis in burn units, even without routine anti-Xa level monitoring. For higher-risk patients — older individuals, larger burns, prolonged ICU stays — clinicians may need to consider more tailored or intensified prevention strategies.
